Hematuria Treatment Market Size & Share Industry Growth 2028

Hematuria Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment (Drugs, Therapies, and Others), Indication (Urinary Tract Infections, Kidney Stones, Urethritis, Blood Cancer, Bladder Stones, Prostate Cancer, Cystitis, Trauma, Vigorous Exercise, Polycystic Kidney Disease, Endometriosis, and Menstruation), Type (Macroscopic Hematuria, Microscopic Hematuria, Idiopathic Hematuria, and Jogger’s Hematuria), and End User (Hospitals, Clinics, and ASC’s, and Others) and Geography

Publication Month : Oct 2021

  • Report Code : TIPRE00004601
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 215
Inquire Before Buy

PRICING

$4550

$2730

The hematuria treatment market is projected to reach US$ 1,103.61 million by 2028 from US$ 932.89 million in 2021; it is expected to grow at a CAGR of 2.4% from 2021 to 2028.

Hematuria is a medical condition indicated by the presence of blood in the urine; under normal circumstances, urine does not contain RBCs. This can result in serious issue that may also cause kidney stones, urinary tract infection, and other inherited diseases. Factors such as the high prevalence of hematuria-associated indications, and increasing awareness about treatment options and improving healthcare expenditure are driving the market. However, the undiagnosed cases of associated indications that hamper the effectiveness of the treatment hinder the hematuria treatment market growth. Further, increasing scope for related treatments is expected to offer significant growth opportunities to the Hematuria Treatment market players to expand their customer base, especially in developing countries.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Hematuria Treatment Market: Strategic Insights

hematuria-treatment-market
Market Size Value inUS$ 932.89 million in 2021
Market Size Value byUS$ 1,103.61 million by 2028
Growth rateCAGR of 2.4% from 2021 to 2028
Forecast Period2021-2028
Base Year2021
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Europe witnessed exponential growth in the number of COVID-19 cases in 2020. Spain, Germany, France, Italy, and the UK are the most affected countries in the region. Proteinuria and hematuria are reported to have a greater prevalence among COVID-19 patients than that in AKI patients. Retrospective studies in China have reported that proteinuria and hematuria are observed in COVID-19 patients, and the conditions also associated with higher mortality. According to the COVID-19 database of the European Kidney Association (ERACODA), established in March 2020, ~25% of kidney transplant patients are diagnosed with SARS-CoV-2. Therefore, the COVID-positive patients are more likely to receive treatments against kidney diseases as well.  

Lucrative Regions for Hematuria Treatment Market

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Market Insights

High Prevalence of Hematuria-Associated Indications Fuels Hematuria Treatment Market Growth

Chronic kidney disease (CKD) is a common and life-threatening condition that affects a larger population worldwide. There are various types of CKDs, such as kidney stones, glomerulonephritis, polycystic kidney disease, and urinary tract infections. CKD is one of the key causes behind the prevalence of hematuria. For instance, according to a study published in the National Center for Biotechnology Information in May 2019, urinary tract infections (UTIs) are generally observed as outpatient infections in the US, mostly occurring among women of the age group between 14 and 24 years. In addition, the prevalence of UTI among women over 65 years of age is about 20% compared to the overall population, which is about 11%. Currently, the global hematuria treatment market is gaining significantly from the increasing prevalence of associated indications. In North America, the U.S. is the largest market for the hematuria treatment market. The growth of this market is primarily driven by the increasing prevalence of chronic kidney disorders (CKD) and growing number of product launches by key players. For instance, in 2016, the Centers for Disease Control and Prevention (CDC) stated that an estimated 0.7 million people were treated for end-stage renal disease (ESRD) in the U.S. The prevalence of ESRD more than doubled between 1990 and 2016. Moreover, the increase in incidence of hematuria among adults, surge in awareness, extensive research & development activities, are also expected to drive the prevalence of hematuria treatments, which will eventually offer a lucrative opportunity for the growth of the market. Increasing geriatric population is also one of the major drivers for this market as aging is the prominent risk factor responsible for growing incidences of renal diseases. For instance, according to a study published by the Population Reference Bureau in 2020, the population age 65 years in the U.S. is expected to double by 2060.

Treatment-Based Insights

The hematuria treatment market, based on treatment, is segmented into drugs, therapies, and others. As hematuria is associated with various indications such as the UTI, kidney stone, blood cancer, bladder stones, and prostate cancer, the drugs used for these indications can also be used for its treatment. Alfuzosin, ciprofloxacin, doxazosin, ibuprofen, and tamsulosin are among the commonly used drugs for the hematuria treatment. This is a preferred treatment type as the drugs can be administered at home and in healthcare settings.

Hematuria Treatment Market, by Treatment – 2020 and 2028

Hematuria Treatment Market, by Treatment – 2020 and 2028
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Indication-Based Insights

The hematuria treatment market, based on indication, is segmented into kidney stones, urinary tract infections (UTI), urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, and menstruation. In 2021, the urinary tract infections segment is likely to hold the largest share of the market. Moreover, the hematuria treatment market for urethritis segment is also expected to register the  fastest CAGR of 3.1% during 2021 to 2028.

Type-Based Insights

The hematuria treatment market, based on type, has been segmented into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria. The macroscopic hematuria segment is likely to hold the largest share of the market in 2021. However, the microscopic hematuria segment is anticipated to register the highest CAGR in the market during the forecast period.

End User-Based Insights

The hematuria treatment market, based on end user, is segmented into hospitals, clinics, ambulatory surgical centers (ASCs), and others. In 2021, the hospitals segment is expected to hold the largest share of the market. Further, the clinics segment is also expected to witness growth in its demand at the fastest CAGR of 6.9% during 2021 to 2028.

Companies operating in the hematuria treatment market adopt the treatment innovations strategy to meet the evolving customer demands across the world, which also permits them to maintain their brand name in the global market.

Hematuria Treatment Market – by Treatment

  • Drugs
  • Therapies
  • Others

Hematuria Treatment Market – by Indication

  • Urinary Tract Infections
  • Kidney Stones
  • Urethritis
  • Blood Cancer
  • Bladder Stones
  • Prostate Cancer
  • Cystitis, Trauma
  • Vigorous Exercise
  • Polycystic Kidney Disease
  • Endometriosis
  • Menstruation

Hematuria Treatment Market – by Type

  • Macroscopic Hematuria
  • Microscopic Hematuria
  • Idiopathic Hematuria
  • Jogger’s Hematuria

Hematuria Treatment Market – by End User

  • Hospitals
  • Clinics
  • ASC’s
  • Others

Hematuria Treatment Market– by Geography

  • North America

    • US
    • Canada
    • Mexico
  • Europe

    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)

    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of APAC
  • Middle East and Africa (MEA)

    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • South and Central America (SCAM)

    • Brazil
    • Argentina
    • Rest of SCAM

 
Company Profiles

  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. HOFFMANN-LA ROCHE LTD.
  • GlaxoSmithKline plc.
  • Janssen Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim International GmbH
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Treatment, Indication, Type, End User and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


What is hematuria treatment?

Hematuria is the presence of blood in the urine. Gross or visible hematuria occurs when the urine is red or pink, indicating the presence of blood in the urine. Blood can sometimes be found in the urine but is difficult to see; this is known as microscopic hematuria since it can only be seen under a microscope. The need for hematuria treatment has increased as the incidence of chronic renal disease and urinary tract infections has increased. Many tests, such as screening for sugar (diabetes), germs (infection), and blood, are performed on a regular basis. Blood can be detected with a chemical strip (also known as a dipstick) or under a microscope.

What are the driving factors for the hematuria treatments market across the globe?

Key factors that are driving the growth of this market are high prevalence of hematuria-associated indications and increasing awareness about treatment options and improving healthcare expenditure are expected to boost the market growth for the hematuria treatments over the years.

What is the market CAGR value of hematuria treatments market during forecast period?

The CAGR value of the hematuria treatments market during the forecasted period of 2021-2028 is 2.4%.

Which treatment type led the hematuria treatments market?

The drugs segment held the largest share of the market in the global hematuria treatments market and held the largest market share of 56.99% in 2020.

Which indication held the largest share in the hematuria treatments market?

The urinary tract infections segment dominated the global hematuria treatments market and accounted for the largest market share of 17.31% in 2020.

Which type held the largest share in the hematuria treatments market?

The macroscopic hematuria segment dominated the global hematuria treatments market and held the largest market share of 48.04% in 2020.

Which end-user held the largest share in the hematuria treatments market?

The hospitals segment dominated the global hematuria treatments market and held the largest market share of 36.52% in 2020.

Who are the key players in the hematuria treatments market?

The hematuria treatments market majorly consists of the players such AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH among others.

The List of Companies - Hematuria Treatment Market

  1. AstraZeneca
  2. Bristol-Myers Squibb Company
  3. F. HOFFMANN-LA ROCHE LTD.
  4. GlaxoSmithKline plc.
  5. Janssen Pharmaceuticals
  6. Merck & Co., Inc.
  7. Novartis AG
  8. Pfizer Inc.
  9. Sun Pharmaceutical Industries Ltd
  10. Boehringer Ingelheim International GmbH

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Hematuria Treatment Market